I-CARE
RSV and FLU Treatment
In adult patients, COVID-19 (Omicron variant), influenza, and RSV present with similar symptoms and can, therefore, be difficult to distinguish. This guide aims to help diagnose and treat Influenza and Respiratory Syncytial Virus (RSV).
For advice on how to protect yourself against infection, see I-PREVENT: COVID, Flu and RSV Protection Protocol. For treatment of COVID-19, see I-CARE: Early COVID Treatment Protocol.
The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. For more information on nutritional therapeutics and how they can help with COVID-19, visit our guide to Nutritional Therapeutics. For more information on vitamins and nutraceuticals during pregnancy, visit our guide to Vitamins and Nutraceuticals During Pregnancy.
For additional information on early treatment, the rationale behind these medications, and other optional treatments, see A Guide to Early Treatment of COVID-19. Early treatment is critical and the most important factor in managing this disease.
Influenza characteristically begins with the abrupt onset of fever, nonproductive cough, and myalgia. Other symptoms include malaise, sore throat, nausea, nasal congestion, and headache. Gastrointestinal symptoms like vomiting and diarrhea are usually not part of influenza in adults.
Older adults (≥65 years) and immunosuppressed patients are more likely to have subtle signs and symptoms; they may present without fever and with milder systemic symptoms than other patients; however, older adults have a higher frequency of altered mental status.
To test for influenza, conventional reverse transcription polymerase chain reaction (RT-PCR) assays are preferred, if available; these are the most sensitive and specific tests for diagnosis of influenza virus infection. An alternative diagnostic test for influenza is an antigen detection assay. These assays have low to moderate sensitivity but high specificity.
RSV is highly infectious, and virtually all individuals have been infected with RSV by the age of two. Previous infection with RSV does not appear to protect against reinfection. Healthy adults are infected with RSV repeatedly throughout their lives and typically have symptoms restricted to the upper respiratory tract.
Signs include cough, cold-like symptoms, runny nose, and conjunctivitis. Compared with other respiratory viruses, RSV is more likely to cause sinus and ear involvement with less prominent fever. RSV is an important and often unrecognized cause of lower respiratory tract infection in older adults and immunocompromised adults.
Diagnosis of RSV is based on a PCR test as well as rapid antigen tests. In adults, the antigen tests have a high specificity however they are less sensitive than PCR-based assays.
Treatment for Influenza and RSV
(Not symptom specific; listed in order of importance.)
This protocol should also be used in patients with an undiagnosed flu-like illness, i.e., those who have not been tested or those whose tests are negative. We would suggest this treatment protocol in those with diagnosed Respiratory Syncytial Virus (RSV); however, in low-risk patients with mild RSV we would suggest omitting Nitazoxanide/ivermectin.
Table 1. How to calculate ivermectin dose
Note that ivermectin is available in different strengths (e.g., 3, 6 or 12 mg) and administration forms (tablets, capsules, drops, etc.). Note that tablets can be halved for more accurate dosing, while capsules cannot.
How much do I weigh? | What dose does the protocol say? | ||||
---|---|---|---|---|---|
In pounds | In kilos | 0.2 mg/kg: | 0.3 mg/kg: | 0.4 mg/kg: | 0.6 mg/kg: |
70-90 | 32-41 | 6-8 mg | 10-12 mg | 13-16 mg | 19-25 mg |
91-110 | 41-50 | 8-10 mg | 12-15 mg | 17-20 mg | 25-30 mg |
111-130 | 50-59 | 10-12 mg | 15-18 mg | 20-24 mg | 30-35 mg |
131-150 | 60-68 | 12-14 mg | 18-20 mg | 24-27 mg | 36-41 mg |
151-170 | 69-77 | 14-15 mg | 21-23 mg | 27-31 mg | 41-46 mg |
171-190 | 78-86 | 16-17 mg | 23-26 mg | 31-35 mg | 47-52 mg |
191-210 | 87-95 | 17-19 mg | 26-29 mg | 35-38 mg | 52-57 mg |
211-230 | 96-105 | 19-21 mg | 29-31 mg | 38-42 mg | 58-63 mg |
231-250 | 105-114 | 21-23 mg | 32-34 mg | 42-45 mg | 63-68 mg |
251-270 | 114-123 | 23-25 mg | 34-37 mg | 46-49 mg | 68-74 mg |
271-290 | 123-132 | 25-26 mg | 37-40 mg | 49-53 mg | 74-79 mg |
291-310 | 132-141 | 26-28 mg | 40-42 mg | 53-56 mg | 79-85 mg |
This protocol is solely for educational purposes regarding potentially beneficial therapies for COVID-19. Never disregard professional medical advice because of something you have read on our website and releases. This protocol is not intended to be a substitute for professional medical advice, diagnosis, or treatment with regard to any patient. Treatment for an individual patient should rely on the judgement of a physician or other qualified health provider. Always seek their advice with any questions you may have regarding your health or medical condition. Please note our full disclaimer at: www.flccc.net/disclaimer.